2014 PBAC submissions and outcomes – winners and losers

Michael Wonder - January 2015

www.maestrodatabase.com

Submissions

The PBAC considered 170 submissions in 2014 of which 168 were prepared and lodged by the pharmaceutical industry (sponsors of medicines and medicinal preparations).

88 (52%) of the 133 submissions were major submissions and 82 (48%) were minor submissions.

Outcomes

The 170 submissions yielded 244 outcomes.  The number of PBAC outcomes from a given PBAC meeting or analysis period may be greater than the number of submissions for the same meeting or analysis period as some submissions may have contained multiple requests and/or multiple patient populations.

Of the 244 outcomes, 157 (64%) were recommendations, 57 (23%) were rejections and 30 (12%) were deferrals.

Winners and losers

The winners for 2014 were MSD (20 recommendations from 6 submissions), Novartis (12 recommendations from 10 submissions), Roche (11 recommendations from 10 submissions) and GSK (8 recommendations from 12 submissions).

The losers for 2014 were Gilead (13 rejections from 1 submission), Sanofi (4 rejections from 3 submissions) and Bayer (4 rejections from 9 submissions).

© Wonder Drug Consulting Pty Ltd, 2015.